PE20001552A1 - Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo - Google Patents
Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseoInfo
- Publication number
- PE20001552A1 PE20001552A1 PE2000000184A PE0001842000A PE20001552A1 PE 20001552 A1 PE20001552 A1 PE 20001552A1 PE 2000000184 A PE2000000184 A PE 2000000184A PE 0001842000 A PE0001842000 A PE 0001842000A PE 20001552 A1 PE20001552 A1 PE 20001552A1
- Authority
- PE
- Peru
- Prior art keywords
- cr5r5
- prostaglandin
- osteoporosis
- alkyl
- prostanoid
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 3
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 229940127293 prostanoid Drugs 0.000 abstract 2
- 150000003814 prostanoids Chemical class 0.000 abstract 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 abstract 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 230000002964 excitative effect Effects 0.000 abstract 1
- JFSPBVWPKOEZCB-UHFFFAOYSA-N fenfuram Chemical compound O1C=CC(C(=O)NC=2C=CC=CC=2)=C1C JFSPBVWPKOEZCB-UHFFFAOYSA-N 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 102000017953 prostanoid receptors Human genes 0.000 abstract 1
- 108050007059 prostanoid receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE UN AGONISTA DE PROSTANOIDE E SUBTIPO 1 (EP1) QUE NO OCURRE NATURALMENTE SELECTIVO PARA EL RECEPTOR EP1 SOBRE OTROS RECEPTORES DE PROSTAGLANDINA EXCITATORIOS Y ADICIONALMENTE SELECTIVO SOBRE OTROS RECEPTORES DE PROSTANOIDES EN UNA RELACION DE 10:1; TAL COMO UN ANALOGO DE PROSTAGLANDINA DE FORMULA I, DONDE: R1 ES CO2H, CONHOH, CO2R3, CH2OH, SO2R3, CONHR3; R3 ES ALQUILO, HETEROALQUILO, CARBOCICLO, HETEROCICLO, ANILLO AROMATICO O HETEROAROMATICO; X ES CH2, O; R2 ES H, ALQUILO; W ES [CR5R5]m-Y-[CR5R5]n-Z, [CR5R5]p-U-[CR5R5]q; R5 ES H, ALQUILO, ALCOXI, HALO; m ES 0-1; n ES 0-1; Y ES CR5R5, NH, S, UN ENLACE; Z ES FENILO, TIENILO, FURANILO, p ES 0-3; q ES 1-3; p+q ES 1-4; U ES CR5R5, NH, S; O 17-FENIL-17-TRINOR PROSTAGLANDINA E2; 9-METILEN-9-DEOXI PROSTAGLANDINA 2; 9-METILEN-9-DEOXI-16,16-DIMETILO PROSTAGLANDINA E2; EL USO DEL AGONISTA DE PROSTANOIDE ES MEDIANTE UNA COMPOSICION TRANSDERMICA POR LO QUE PUEDE SER UTIL PARA AUMENTAR EL VOLUMEN OSEO, AUMENTAR EL VOLUMEN TRABECULAR, TRATAMIENTO DE LA OSTEOPOROSIS, OSTEOPOROSIS POSMENOPAUSICA, OSTEOARTRITIS, ENFERMEDAD DE PAGET, OSTEOMALACIA, FRACTURA OSEA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12306399P | 1999-03-05 | 1999-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001552A1 true PE20001552A1 (es) | 2001-01-30 |
Family
ID=22406507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000184A PE20001552A1 (es) | 1999-03-05 | 2000-03-03 | Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1158969A2 (es) |
| JP (1) | JP2002538105A (es) |
| AU (1) | AU3711900A (es) |
| CA (1) | CA2366755A1 (es) |
| CO (1) | CO5150205A1 (es) |
| IL (1) | IL145128A0 (es) |
| NO (1) | NO20014192L (es) |
| NZ (1) | NZ513828A (es) |
| PE (1) | PE20001552A1 (es) |
| WO (1) | WO2000051585A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006118173A1 (ja) | 2005-04-28 | 2006-11-09 | Ono Pharmaceutical Co., Ltd. | 経皮吸収製剤 |
| EP2085088A4 (en) | 2006-10-26 | 2012-08-29 | Ono Pharmaceutical Co | ADHESIVE PREPARATION |
| US20110038884A1 (en) | 2008-04-28 | 2011-02-17 | National University Co., Hamamatsu Univer. School Of Medicine | Immunopotentiating agent comprising ep1 agonist |
| EP2542263A4 (en) * | 2010-03-05 | 2013-07-31 | Univ Rochester | EP1 INHIBITION |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3982016A (en) * | 1975-08-06 | 1976-09-21 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
| US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
| US4812304A (en) * | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Treatment of osteoporosis |
| AU2146592A (en) * | 1991-05-29 | 1993-01-08 | Sepracor, Inc. | Combination of nsaids and prostaglandins and uses therefor |
| KR20010023840A (ko) * | 1997-09-09 | 2001-03-26 | 데이비드 엠 모이어 | 비천연 선택성 ｆｐ 아고니스트를 이용한 골 부피 증가 방법 |
| WO2000021542A1 (en) * | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for stimulating bone formation |
| AU3385900A (en) * | 1999-03-05 | 2000-09-21 | Procter & Gamble Company, The | Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives |
-
2000
- 2000-03-01 EP EP00915937A patent/EP1158969A2/en not_active Withdrawn
- 2000-03-01 AU AU37119/00A patent/AU3711900A/en not_active Abandoned
- 2000-03-01 WO PCT/US2000/005196 patent/WO2000051585A2/en not_active Ceased
- 2000-03-01 NZ NZ513828A patent/NZ513828A/xx not_active Application Discontinuation
- 2000-03-01 CA CA002366755A patent/CA2366755A1/en not_active Abandoned
- 2000-03-01 IL IL14512800A patent/IL145128A0/xx unknown
- 2000-03-01 JP JP2000602053A patent/JP2002538105A/ja not_active Withdrawn
- 2000-03-03 PE PE2000000184A patent/PE20001552A1/es not_active Application Discontinuation
- 2000-03-06 CO CO00016009A patent/CO5150205A1/es unknown
-
2001
- 2001-08-29 NO NO20014192A patent/NO20014192L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002538105A (ja) | 2002-11-12 |
| EP1158969A2 (en) | 2001-12-05 |
| WO2000051585A3 (en) | 2001-01-25 |
| AU3711900A (en) | 2000-09-21 |
| CA2366755A1 (en) | 2000-09-08 |
| NO20014192D0 (no) | 2001-08-29 |
| IL145128A0 (en) | 2002-06-30 |
| WO2000051585A2 (en) | 2000-09-08 |
| NO20014192L (no) | 2001-11-05 |
| CO5150205A1 (es) | 2002-04-29 |
| NZ513828A (en) | 2001-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04004457A (es) | Novedosos derivados de 1,2,4-tiadiazolio como moduladores del receptor de melanocortina. | |
| NZ525700A (en) | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor | |
| MXPA04000454A (es) | Derivados de 2-pirrolidona como agonistas de prostanoides. | |
| CO5251453A1 (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis | |
| PE20020637A1 (es) | Derivados de 5-oxo-pirrolidina como agonistas de prostaglandinas | |
| PE20010817A1 (es) | Compuestos para el tratamiento de la disfuncion sexual femenina | |
| TR200003383T2 (tr) | HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler. | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| CO5210903A1 (es) | Composiciones novedosas de mezcla de aceite | |
| EA200600188A1 (ru) | Производные пиримидин-2,4-диона и их применение в качестве антагонистов рецепторов гонадолиберина | |
| BR0010348A (pt) | Uso de antagonistas seletivos de receptor <244>~ 1b~-adrenérgico para aperfeiçoamento de disfunção sexual | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| NZ509239A (en) | 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents | |
| PT1445258E (pt) | Activador para o receptor delta activado por proliferador de peroxissoma | |
| BRPI0519188A2 (pt) | composiÇço detergente lÍquida substancialmente nço-aquosa, envelope de polÍmero solével em Água, e, uso de composiÇço ou de envelope | |
| PE119099A1 (es) | Metodo para aumentar el volumen oseo utilizando agonistas selectivos fp que no ocurren naturalmente | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| PE20020844A1 (es) | Derivados de imidazolilo como inhibidores del factor de liberacion de la corticotropina | |
| PE71599A1 (es) | Inhibidores de proteasas | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| NZ508560A (en) | Use of prostaglandin agonists to treat erectile dysfunction or impotence | |
| PE20001552A1 (es) | Uso de agonistas ep1 selectivos que no ocurren naturalmente para aumentar el volumen oseo | |
| NO20033959D0 (no) | Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon | |
| CY1106863T1 (el) | Βιολογικως δραστικες 4h-βενζο[1,4]οξαζιν-3-ονες | |
| DE60208803D1 (de) | 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AE | Restoration of lapsed or forfeited application | ||
| FC | Refusal |